<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363868</url>
  </required_header>
  <id_info>
    <org_study_id>CA180-568</org_study_id>
    <nct_id>NCT02363868</nct_id>
  </id_info>
  <brief_title>Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population</brief_title>
  <official_title>Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the healthcare costs among patients with CML
      receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured
      population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Healthcare costs</measure>
    <time_frame>Intent-to-treat (ITT) at 6 months</time_frame>
    <description>Average (mean) costs for patients receiving dasatinib or nilotinib as first line therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healthcare costs by line of therapy</measure>
    <time_frame>Intent-to-treat (ITT) at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource utilization by line of therapy</measure>
    <time_frame>Intent-to-treat (ITT) at 6 months</time_frame>
    <description>Captured per number of hospitalizations, Emergency room (ER) visits, physician office visits, and medications / number of prescriptions</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">186</enrollment>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <arm_group>
    <arm_group_label>CML subjects receiving Dasatinib</arm_group_label>
    <description>CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CML subjects receiving Nilotinib</arm_group_label>
    <description>CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Others: Retrospecitve database analysis of patients in a health plan
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Age &gt;18 years

          -  International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9
             CM) code for CML (205.1x)

          -  At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013

          -  Continuous eligibility for the 6 months pre- and post-index date (defined as the date
             of first fill for dasatinib or nilotinib)

        Exclusion Criteria:

          -  History of bone marrow or stem cell transplant as identified in the 6 month pre-period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franklin Pharmaceutical Consulting, Llc</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <zip>29325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

